Encellin develops an Encapsulated Cell Replacement Therapy (EnCRT) designed to isolate therapeutic cells from the immune system while allowing exchange of biomolecules to support cell function. The platform uses biocompatible, permeable nanofabricated membranes to create soft pouches that aim to enable implanted cells to act as living medicines. Preclinical data for its first candidate, ENC-201, showed no fibrosis or immune response while maintaining cell viability and function, and primary islets encapsulated in EnCRT may be able to reverse Type 1 Diabetes. The company plans to advance a Phase 1 clinical trial of subcutaneous transplantation of primary islets within EnCRT, with first-in-human data expected next year. Funding will also support team expansion and further development of the technology platform, which the company says can be applied across chronic endocrine disorders. Encellin’s technology is based on UCSF Desai lab research and its team includes experts in biomaterials, medical devices, and cell therapies with prior IPO and commercial experience. Encellin is a regenerative medicine company developing soft, nanoporous cell‑encapsulation devices (CEDs) that act as pouches to house therapeutic cells and release therapies as needed. Its platform combines novel cell encapsulation technology with functional cell therapies, initially targeting hypoglycemia in Type 1 diabetes and hypocalcemia in dialysis patients. The company plans to advance programs using readily available renewable cell sources and engineered cells to encapsulate varied cellular cargos. The new $5.9M seed financing will be used to advance the technology platform and programs, build out a laboratory, and expand the team. Encellin’s founding team from UCSF leads its work in nanotechnology and bioengineering, and the company is headquartered in San Francisco. Crystal Nyitray, Ph.D., serves as CEO and co‑founder.

Total raised

$16M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2023